Short-Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open-Label, Randomised Controlled Trial

What Was Tested

Researchers studied Tirzepatide in this randomized controlled trial publication.

Who Took Part

According to the abstract, 16, participants were involved.

By PubMed's age tags, the people studied were young adults and adults, women only.

Secondary outcomes included changes in anthropometric measures other than body weight, body composition, reproductive hormone levels, metabolic and endocrine parameters, inflammatory markers and menstrual cycle regularity.

After week 16, participants were switched to MET monotherapy.

How the Study Was Run

The design is described as randomized.

Random assignment meant chance, not the researchers, decided who got Tirzepatide and who got the comparison, which limits bias.

The timeline in the abstract includes 8 weeks.

The primary outcome was the change in body weight.

All outcomes were assessed at baseline and week 16.

Barrier contraception was required for 8 weeks and pregnancy outcomes were subsequently evaluated between weeks 25 and 48.

What Was Measured

The subject headings attached to it are Body Mass Index, China, Hypoglycemic Agents, Metformin, Obesity, Overweight and Polycystic Ovary Syndrome.

Author keywords: body composition, pregnancy and tirzepatide.

What This Means in Plain Language

The paper is a randomized study of Tirzepatide in 16, participants over 8 weeks.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Tirzepatide compound page, all human trials.